Cardiovascular Therapeutics Targets on the NO-sGC-cGMP Signaling Pathway: A Critical Overview

Current Drug Targets

Volumn 13, Issue 9, 2012, Pages 1207-1214

  Evora, Paulo Roberto B ^a   Evora, Patricia M ^a   Celotto, Andrea C ^a   Rodrigues, Alfredo J ^a   Joviliano, Edwaldo E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Nitric oxide; Nitric oxide blockers; Nitric oxide enhancers; Nitric oxide synthase; Nitric oxide uncoupling; Soluble guanylate cyclase

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ATACIGUAT; AVE 3085; AVE 9488; CARDIOVASCULAR AGENT; CFM 1571; CINACIGUAT; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; GUANYLATE CYCLASE INHIBITOR; LIFICIGUAT; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NELOCIGUAT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; RIOCIGUAT; SILDENAFIL; TADALAFIL; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; VARDENAFIL;

ATHEROSCLEROSIS; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG TARGETING; HEART FAILURE; HUMAN; ISCHEMIC CARDIOMYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; CARDIOVASCULAR DISEASES; CYCLIC GMP; GUANYLATE CYCLASE; HUMANS; NITRIC OXIDE; SIGNAL TRANSDUCTION;

EID: 84864599029     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012802002348     Document Type: Review

References (46)

1. Gielis JF, Lin JY, Wingler K, et al. Pathogenetic role of eNOSuncoupling in cardiopulmonary disorders. Free Radic Biol Med 2011; 50: 765-76.
2. Förstermann U, Li H. Therapeutic effect of enhancing endothelialnitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 2011; 164: 213-23.
3. Wohlfart P, Xu H, Endlich A, et al. Antiatherosclerotic effects ofsmall-molecular-weight compounds enhancing endothelial nitricoxidesynthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther 2008; 325: 370-9.
4. Xue HM, He GW, Huang JH, et al. New strategy of endothelialprotection in cardiac surgery: use of enhancer of endothelial nitricoxide synthase. World J Surg 2010; 34: 1461-9.
5. Zhang Y, Janssens SP, Wingler K, et al. Modulating endothelialnitric oxide synthase: a new cardiovascular therapeutic strategy. Am J Physiol Heart Circ Physiol 2011; 301: H634-46.
6. Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulatorsand activators of soluble guanylate cyclase: discovery andtherapeutic potential. Nat Rev Drug Discov 2006; 5: 755-68.
7. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as anemerging therapeutic target in cardiopulmonary disease. Circulation2011; 123: 2263-73.
8. Boerrigter G, Burnett JC Jr. Nitric oxide-independent stimulationof soluble guanylate cyclase with BAY 41-2272 in cardiovasculardisease. Cardiovasc Drug Rev 2007; 25: 30-45
9. Rybalkin SD, Yan C, Bornfeldt KE, et al. Cyclic GMP phosphodiesterasesand regulation of smooth muscle function. Circ Res 2003;93: 280-91.
10. Evora PR, Ribeiro PJ, Vicente WV, et al. Methylene blue forvasoplegic syndrome treatment in heart surgery: fifteen years ofquestions, answers, doubts and certainties. Rev Bras Cir Cardiovasc2009; 24: 279-88.
11. Evora PR, Simon MR. Role of nitric oxide production in anaphylaxisand its relevance for the treatment of anaphylactic hypotensionwith methylene blue. Ann Allergy Asthma Immunol 2007; 99:306-13.
12. Evora PR, Viaro F. The guanylyl cyclase inhibition by MB asvasoplegic circulatory shock therapeutical target. Curr Drug Targets2006; 7: 1195-204.
13. Bai Y, Sun L, Yang T, et al. Increase in fasting vascular endothelialfunction after short-term oral L-arginine is effective when baselineflow-mediated dilation is low: a meta-analysis of randomized controlledtrials. Am J Clin Nutr 2009; 89: 77-84.
14. Lass A, Suessenbacher A, Wolkart G, et al. Functional and analyticalevidence for scavenging of oxygen radicals by L-arginine. MolPharmacol 2002; 61: 1081-8.
15. Antoniades C, Shirodaria C, Leeson P, et al. Association of plasmaasymmetrical dimethylarginine (ADMA) with elevated vascularsuperoxide production and endothelial nitric oxide synthase uncoupling:implications for endothelial function in human atherosclerosis. Eur. Heart J 2009; 30: 1142-50.
16. Schulman SP, Becker L C, Kass DA, et al. L-Arginine therapy inacute myocardial infarction: the Vascular Interaction with Age inMyocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295: 58-64.
17. Bode-Boger SM, Scalera F, Ignarro LJ. The L-arginine paradox:importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 2007; 114: 295-306.
18. Heitzer T, Krohn K, Albers S, et al. Tetrahydrobiopterin improvesendothelium-dependent vasodilation by increasing nitric oxide activityin patients with type II diabetes mellitus. Diabetologia 2000;43: 1435-8.
19. Ramzy D, Rao V, Tumiati LC, et al. Tetrahydrobiopterin preventscyclosporine-induced vasomotor dysfunction. Transplantation2005; 79: 876-81.
20. Grabowski PS, Wright PK, Van 't Hof RJ, et al. Immunolocalizationof inducible nitric oxide synthase in synovium and cartilage inrheumatoid arthritis and osteoarthritis. Br J Rheumatol 1997; 36:651-5.
21. Porkert M, Sher S, Reddy U, et al. Tetrahydrobiopterin: a novelantihypertensive therapy. J Hum Hypertension 2008; 22: 401-7.
22. Katusic ZS, D'Uscio LV, Nath KA. Vascular protection by tetrahydrobiopterin:progress and therapeutic prospects. Trends PharmacolSci 2009; 30: 48-54.
23. Moens, AL, Vrints CJ, Claeys MJ, et al. A Mechanisms and potentialtherapeutic targets for folic acid in cardiovasculardisease. Am JPhysiol Heart Circ Physiol 2008; 294: H1971-7.
24. Moens AL, Claeys MJ, Wuyts FL, et al. Effect of folic acid onendothelial function following acute myocardial infarction. Am JCardiol 2007; 99: 476-81.
25. Setoguchi S, Mohri M, Shimokawa H, et al. Tetrahydrobiopterinimproves endothelial dysfunction in coronary microcirculation inpatientswithout epicardial coronary artery disease. J Am Coll Cardiol2001; 38: 493-8.
26. Verhaar MC, Wever RM, Kastelein JJ, et al. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelialfunction in familial hypercholesterolemia. Circulation 1998;97: 237-41.
27. Shirodaria C, Antoniades C, Lee J, et al. Global improvement ofvascular function and redox state with low-dose folicacid: implicationsfor folate therapy in patients with coronary artery disease. Circulation 2007; 115: 2262-70.
28. Sasaki K, Heeschen C, Aicher A, et al. Ex vivo pretreatment ofbone marrow mononuclear cells with endothelial NO synthase enhancerAVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 2006; 103: 14537-41.
29. Fraccarollo D, Widder JD, Galuppo P, et al. Improvement in leftventricular remodeling by the endothelial nitric oxide synthase enhancerAVE9488 after experimental myocardial infarction. Circulation2008; 118: 818-27.
30. ISIS-4-Group. ISIS-4: a randomized factorial trial assessing earlyoral captopril, oral mononitrate, and intravenous magnesium sulphatein 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) CollaborativeGroup. Lancet 1995; 345: 669-85.
31. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrateandrecommendations for its use. Am J Cardiol 1999; 84: 11N-7N.
32. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000;86: 57F-61F.
33. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacyand side effects of the PDE-5 inhibitors sildenafil, vardenafiland tadalafil: review of the literature. Eur J Med Res 2002; 7: 435-46.
34. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonaryhypertension. N Engl J Med 2000; 343: 1342.
35. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effectiveand specific pulmonary vasodilator in patients with pulmonaryarterial hypertension: comparison with inhaled nitric oxide. Circulation2002; 105: 2398-403.
36. Evora PR. An open discussion about endothelial dysfunction: is ittimely to propose a classification? Int J Cardiol 2000;31;73:289-92.
37. Evora PR, Baldo CF, Celotto AC, et al. Endothelium dysfunctionclassification: why is it still an open discussion? Int J Cardiol 2009;137: 175-6.
38. Hochman JS. Cardiogenic shock complicating acute myocardialinfarction:expanding the paradigm. Circulation 2003; 107: 2998-3002.
39. Cotter G, Kaluski E, Milo O, Blatt A, et al. L-NAME (a NO synthaseinhibitor) in the treatment of refractory cardiogenic shock: aprospective randomized study. Eur Heart J 2003; 24: 1287-95.
40. Bailey A, Pope TW, Moore SA, et al. The tragedy of TRIUMPHfor nitric oxide synthesis inhibition in cardiogenic shock: where dowe go from here? Am J Cardiovasc Drugs 2007; 7: 337-45.
41. TRIUMPH Investigators, Alexander JH, Reynolds HR, et al. Effectof tilarginine acetate in patients with acute myocardial infarctionand cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007; 297: 1657-66.
42. Howes LG, Brillante DG. Expert opinion on tilarginine in thetreatment of shock. Expert Opin Investig Drugs 2008; 17: 1573-80.
43. Evora PR, Roselino CH, Schiaveto PM. Methylene blue in anaphylacticshock. Ann Emerg Med 1997; 30: 240.
44. Evora PR, Rodrigues AJ, Vicente WV, et al. Is the cyclic GMPsystem underestimated by intensive care and emergency teams?Med Hypotheses 2007; 69: 564-7.
45. Evora PR, Levin RL. Methylene blue as drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass. J ThoracCardiovasc Surg 2004; 127: 895-6.
46. Beavo JA, Brunton LL. Cyclic nucleotide research: still expandingafter half a century. Nat Rev Mol Cell Biol 2002; 3: 710-8.